Double standards? Dr. Mobeen Syed reviews the hurdles faced by ivermectin and molnupiravir in the COVID pandemic

Dr. Mobeen Syed aka “Dr. Been” has become a sensation on YouTube educating millions on various medical topics during this difficult pandemic including refreshingly sincere lessons on topics such as ivermectin. Most recently the online doc raised concern over the inconsistent criteria applied in ivermectin and molnupiravir trials in the quest to get authorization for the treatment of COVID-19. TrialSite has covered Dr. Been’s previous examinations of potential COVID treatments, including how his YouTube channel was censored for discussing information related to hydroxychloroquine, remdesivir, and ivermectin.

In a YouTube video streamed on October 7, 2021, Dr. Been contrasts the methods used by the FDA and CDC for approval of COVID treatments. Dr. Been emphasizes the lack of impartiality, and preferential treatment in the recommendation guidelines by the FDA and CDC.

He claims that there are clear signs of preferential allowances in the molnupiravir trial and in other recommended drugs (remdesivir, bamlanivimab) when applying for emergency use authorization (EUA). Meanwhile, ivermectin clinical trials are repeatedly disqualified.

Recap of Molnupiravir Timeline


Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee